Details

Autor(en) / Beteiligte

• Boonen, Steven
• Reginster, Jean-Yves
• Kaufman, Jean-Marc
• Lippuner, Kurt
• Zanchetta, Jose
• Langdahl, Bente
• Rizzoli, Rene
• Lipschitz, Stanley
• Dimai, Hans Peter
• Witvrouw, Richard
• Eriksen, Erik
• Brixen, Kim
• Russo, Luis
• Claessens, Frank
• Papanastasiou, Philemon
• Antunez, Oscar
• Su, Guoqin
• Bucci-Rechtweg, Christina
• Hruska, Josef
• Incera, Elodie
• Vanderschueren, Dirk
• Orwoll, Eric

Titel

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Ist Teil von

• The New England journal of medicine, 2012-11, Vol.367 (18), p.1714-1723

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• This multicenter trial evaluated zoledronic acid versus placebo in men with osteoporosis for a primary end point of new morphometric vertebral fracture over 24 months. Zoledronic acid was associated with a significantly reduced risk of vertebral fracture. Osteoporosis is an important cause of morbidity and mortality among men. 1 , 2 Among persons older than 50 years of age, approximately 40% of all osteoporotic fractures worldwide occur in men. 3 Mortality after osteoporotic fracture is higher among men than among women. 2 , 4 Previous studies involving men with osteoporosis have focused on the surrogate outcomes of bone mineral density and bone-turnover markers, 5 – 9 but data from double-blind, randomized studies assessing antifracture efficacy are lacking. In addition, given the low awareness of the disease, 10 the development of guidelines for the detection and treatment of osteoporosis in men has been limited. 11 Hence, there . . .